A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Shifu Xiao(Shanghai Jiao Tong University), Raoli He(Fujian Medical University), Benyan Luo(Allen Institute for Brain Science), Shengdi Chen(Shanghai Jiao Tong University), Yun‐Cheng Wu(Shanghai Jiao Tong University), Wei Zhang(Shihezi University), Zhonglin Liu(Sun Yat-sen University), Xiaoping Pan(Guangzhou First People's Hospital), Qianhua Zhao(Fudan University), Yong Ji(Tianjin Huanhu Hospital), Yang Lü(The Affiliated Yongchuan Hospital of Chongqing Medical University), Piu Chan(Capital Medical University), Ying Peng(Sun Yat-sen University), Lijun Jiang(Sichuan University), Jun Xu(Beijing Tongren Hospital), Yingjun Ouyang(Guangzhou First People's Hospital), Wenwei Ren(Wenzhou Medical University), Yuying Zhou(Tianjin University), Shuzhen Wang(China Pharmaceutical University), Dantao Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Qihao Guo(Fudan University), Shuai Liu(Tongji University), Yan Wang(Nankai University), Nan Zhang(Peking University), Wei Chen(Sir Run Run Shaw Hospital), Xiaowei Liu(Guangxi University), Yi Li(Shanghai University of Traditional Chinese Medicine), Tao Wang(Shanghai Jiao Tong University), Xiaoping Wang(Shanghai Jiao Tong University), Yan Cheng(Tianjin Medical University General Hospital), Shuhua Li(Chinese Academy of Sciences), Chun‐Feng Liu(Soochow University), Lu‐Ning Wang(University of Science and Technology Beijing), Jianjun Jia(Chinese PLA General Hospital), Qiumin Qu(First Affiliated Hospital of Xi'an Jiaotong University), Zhongxin Zhao(Shanghai Changzheng Hospital), Weixian Chen(Dalian Medical University), Junjian Zhang(Wuhan University), Yansheng Li(Renji Hospital), Yongtao Zhou(Capital Medical University), Zhen Hong(Fudan University), Yong Yan(Xiamen University), Wenyuan Wu(Tongji University), Qinyong Ye(Fujian Medical University), Dongsheng Fan(Peking University), Jincai He(Wenzhou Medical University), Peixian Mao(Capital Medical University), Weihong Kuang(First Affiliated Hospital of Guangzhou University of Chinese Medicine), Qiumei Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yifeng Du(Ministry of Education)
Cited by 200
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
|Signal Transduction and Targeted Therapy|2023|1.3k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
Reduced default mode network functional connectivity in patients with recurrent major depressive disorder
|Proceedings of the National Academy of Sciences|2019|865